TIANJIN DEV(00882): Tianjin Lisheng Pharmaceutical(002393.SZ)'s annual net profit attributable to shareholders is 416 million RMB, a year-on-year increase of 125.59%.

06:43 25/03/2026

Tianjin Development (00882) released the annual performance of Lisen Pharmaceutical (002393.SZ) ending on December 31, 2025. The company's operating income was 1.392 billion yuan, an increase of 4.18% year-on-year. Net profit attributable to shareholders of the listed company was 416 million yuan, an increase of 125.59% year-on-year. Basic earnings per share was 1.62 yuan.

TIANJIN DEV (00882) announces the annual performance of Tianjin Lisheng Pharmaceutical (002393.SZ) as of December 31, 2025. The company's operating income was 1.392 billion yuan, an increase of 4.18% year-on-year. Net profit attributable to the shareholders of the listed company was 416 million yuan, an increase of 125.59% year-on-year. Basic earnings per share were 1.62 yuan.

CEOVU (00798) will distribute a final dividend of HK $0.0049 per share on October 30th.

HESAI-W(02525) issued a total of 785,400 rewards.

KEEP (03650) releases annual performance, with adjusted net profit of 25.216 million yuan, gross profit margin increased to 52.2%, kicking off AI strategic transformation.

CEOVU (00798) will distribute a final dividend of HK $0.0049 per share on October 30th.

HESAI-W(02525) issued a total of 785,400 rewards.

KEEP (03650) releases annual performance, with adjusted net profit of 25.216 million yuan, gross profit margin increased to 52.2%, kicking off AI strategic transformation.